The combination of intestinal inhibition of FXR and prebiotic supplementation may constitute a promising approach in the management of metabolic disorders such as type 2 diabetes and their complications such as NAFLD and cardiovascular diseases. This evidence concerns the gene NR1H4 and metabolic disease.